{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8890","upperLimit":"0.9878","value":"0.9628"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"1","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"235"}],"units":"Participants"}],"description":"OS distributions will be estimated by the Kaplan-Meier method for patients with high risk features according to central review and treated with adjuvant chemotherapy and separately for subjects with central review recommendation of enucleation alone.","dispersionType":"95% Confidence Interval","groups":[{"description":"Includes patients who may or may not require chemotherapy. Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity and patients who complete chemotherapy are followed after completion of therapy periodically for at least 5 years. Patients who do not require chemotherapy undergo observation periodically for at least 5 years.","id":"OG000","title":"Group 1 (Identified by Central Review as High Risk)"},{"description":"Patients undergo observation periodically for at least 5 years.","id":"OG001","title":"Group 2 (Identified by Central Review as Not High Risk)"}],"paramType":"NUMBER","populationDescription":"Only eligible patients are considered for this outcome measure. This is calculated as the total number of patients enrolled in each group with the number ineligible in each group subtracted as reported on the participant flow template.","reportingStatus":"POSTED","timeFrame":"At 2 Years","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Estimated Probability"}